Status:
COMPLETED
The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM)
Lead Sponsor:
ECbiotech Taiwan
Conditions:
Diabetes Mellitus, Type II
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to examine whether the extract of the Agaricus blazei Murill mushroom is effective in the supplementary treatment of type II DM patients.
Detailed Description
The researchers have the animal model that the extract of the Agaricus blazei Murill mushroom is effective in the treatment of type II DM mice conducted on 2002. The dose effects were also found. The ...
Eligibility Criteria
Inclusion
- Type II DM
- Age 20-75 years old
- Treat with Gliclazide and Metformin
- Signed informed consent
Exclusion
- GOT/GPT \>80/80
- Creatinine \> 2.0
- Lactating or pregnant women
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00131287
Start Date
July 1 2005
End Date
December 1 2006
Last Update
January 5 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung-Hua Hsu
Taipei, Taiwan, 886